X-linked Mental Retardation Clinical Trial
Official title:
Clinical Phenotyping and Characterization of Neural Networks and Cognitive Processes Involved in Mental Retardation X-linked
X-linked Mental retardation (XLMR) represent 10% of the causes of mental retardation with a
prevalence in both sexes around 1/296, i.e. 3.3 / 1000 births (Opitz et al., 1986). This
heterogeneous group of XLMR includes dozens of rare diseases, some of them affecting only a
few patients. Molecular diagnosis is currently available in France for 25 XLMR genes, within
the national network of XLMR molecular diagnosis. However, whereas some syndromes such as
Fragile X syndrome, are now well clinically defined, this is not the case for recently
identified syndromes for which very few data is available, preventing clinicians to focus
molecular diagnosis on a specific gene.
Therefore, this study aims to :
- Achieve a description of the clinical phenotype specific to each XLMR gene (Phase 1 of
the study, n=200)
- Characterize the cognitive learning mechanisms and dysfunctional neural networks
involved (Phase 2 of the study, n=75, i.e. 5 groups of 15 patients with a mutation in
the same gene). These two elements constitute key steps to develop appropriate
rehabilitation strategies and targeted pharmacological therapies.
Moreover, the impact of mental retardation on the primary caregiver within the family and the
induced burden in terms of psycho-social, organizational and economic burden will also be
assessed. These elements, directly related to the patient's environment, are very important
to characterize in order to better understand the consequences of each gene mutation (Phase 3
of the study, n=283). For example, it is necessary to better understand the impact of Fragile
X syndrome in terms of capacity and behavior, lifestyle, and health care needs of the
patients While advancing knowledge allows to consider innovative therapeutics, the
implementation of these therapeutics and assessment of their impact on the patients' life
trajectory, require precise characterization of the population to be treated in medico
socioeconomic terms.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00916903 -
Genetic Disease Gene Identification
|